Cargando…

Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer

Immune monotherapy does not appear to work in patients with pancreatic cancer so far. We are conducting a clinical trial that combines programmed cell death protein-1 (PD-1) inhibitor with chemotherapy and concurrent radiotherapy as induction therapy for patients with locally advanced pancreatic can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Changchang, Zhu, Yahui, Cheng, Hao, Kong, Weiwei, Zhu, Linxi, Wang, Lei, Tang, Min, Chen, Jun, Li, Qi, He, Jian, Li, Aimei, Qiu, Xin, Chen, Dongsheng, Meng, Fanyan, Qian, Xiaoping, Liu, Baorui, Qiu, Yudong, Du, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207502/ https://www.ncbi.nlm.nih.gov/pubmed/35734594 http://dx.doi.org/10.3389/fonc.2022.898119

Ejemplares similares

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer
por: Lu, Changchang, et al.
Publicado: (2022)

Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy
por: Du, Juan, et al.
Publicado: (2022)

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023)

PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial
por: Du, Juan, et al.
Publicado: (2023)

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer
por: Du, Juan, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
por: Gong, Xiaoling, et al.
Publicado: (2022)

Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
por: Shao, Jie, et al.
Publicado: (2022)

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study
por: Dai, Wangshu, et al.
Publicado: (2021)

Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer
por: Shi, Zhan, et al.
Publicado: (2022)

Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report
por: Kong, Weiwei, et al.
Publicado: (2019)

Radiotherapy for patients with completely resected pathologic IIIA(N2) non–small-cell lung cancer: a retrospective analysis
por: Zhu, Ying, et al.
Publicado: (2019)

A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines
por: Shi, Tianyu, et al.
Publicado: (2023)

Folate receptor-positive circulating tumor cells predict survival and recurrence patterns in patients undergoing resection for pancreatic cancer
por: Cheng, Hao, et al.
Publicado: (2022)

Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value
por: Qiu, Miaozhen, et al.
Publicado: (2016)

Radiomics-based model for predicting early recurrence of intrahepatic mass-forming cholangiocarcinoma after curative tumor resection
por: Zhu, Yong, et al.
Publicado: (2021)

The role of preoperative biliary drainage on postoperative outcome after pancreaticoduodenectomy in patients with obstructive jaundice
por: Zhu, Linxi, et al.
Publicado: (2023)

Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review
por: Gostimir, Mišo, et al.
Publicado: (2016)

Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing
por: Chen, Kai, et al.
Publicado: (2023)

Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation
por: Wang, A-min, et al.
Publicado: (2021)

Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer
por: Du, Juan, et al.
Publicado: (2017)

Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer
por: Zhu, Yahui, et al.
Publicado: (2022)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Pathological complete response following neoadjuvant radiotherapy and intraperitoneal perfusion chemotherapy for recurrent colon carcinoma: A case report and literature review
por: BIAN, XINYU, et al.
Publicado: (2016)

Distribution and pathological features of pancreatic, ampullary, biliary and duodenal cancers resected with pancreaticoduodenectomy
por: Chandrasegaram, Manju D, et al.
Publicado: (2015)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma
por: Dal Molin, Marco, et al.
Publicado: (2016)

Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma
por: Zhou, Chong, et al.
Publicado: (2022)

Groove resection of pancreatic head in groove pancreatitis: A case report
por: Zhu, Chunfu, et al.
Publicado: (2017)

Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors (Adv. Sci. 12/2023)
por: Wang, Xinyue, et al.
Publicado: (2023)

Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors
por: Wang, Xinyue, et al.
Publicado: (2023)

YAP-Dependent Induction of CD47-Enriched Extracellular Vesicles Inhibits Dendritic Cell Activation and Ameliorates Hepatic Ischemia-Reperfusion Injury
por: Yuan, Zenan, et al.
Publicado: (2021)

Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
por: Zhang, Chao, et al.
Publicado: (2022)

Apparent Diffusion Coefficient Predicts Pathology Complete Response of Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy
por: Chen, Yuan-Gui, et al.
Publicado: (2016)

Vater’s ampullary carcinoma increases the risk of clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy: A retrospective and propensity score-matched analysis
por: Yang, Yifei, et al.
Publicado: (2022)

High endothelial venule is a prognostic immune‐related biomarker in patients with resected intrahepatic cholangiocarcinoma
por: Zhou, Yan, et al.
Publicado: (2023)

Robotic circumferential tracheal resection and reconstruction via a completely portal approach
por: Qiu, Tong, et al.
Publicado: (2018)

Use of Pulsed Low–Dose Rate Radiotherapy in Refractory Malignancies()()
por: Yan, Jing, et al.
Publicado: (2018)

Association of Smoking and Respiratory Disease History with Pancreatic Pathologies Requiring Surgical Resection
por: Ream, Carolyn, et al.
Publicado: (2023)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n1ln7g86svr045ktqoacfcalgo